Skip to main content
SpringerPlus

Table 4 Results of the univariate and multivariate analyses of factors associated with the bRFS after definitive radiotherapy

From: Definitive 3D-CRT for clinically localized prostate cancer: modifications of the clinical target volume following a prostate MRI and the clinical benefits

 

n

Univariate

Multivariatef

5-year (%)

p

OR (95% CI)

p

Age (years)

  

<0.01

1.71 (0.99–2.99)

0.06

 <70

130

82

   

 >71

280

90

   

T stagea

  

<0.01

1.88 (0.96–3.71)

0.07

 T1–2

315

92

   

 T3–4

95

74

   

iPSA (ng/mL)b

  

<0.01

1.76 (0.83–3.72)

0.14

≦20

258

91

   

 >20

151

82

   

Gleason scorec

  

<0.01

3.06 (1.60–5.81)

<0.001

 2–7

308

91

   

 8–10

92

75

   

Risk groupd

  

<0.01

1.30 (0.47–3.63)

0.62

 Low-intermediate risk

191

92

   

 High-very high risk

214

83

   

Date of treatment

  

0.11

1.41 (0.66–3.02)

0.37

 1998–2005

199

90

   

 2006–2009

211

86

   

ADT (months)e

  

0.45

1.07 (0.47–2.44)

0.87

 <6

63

91

   

≧6

338

88

   

Radiation dose

  

0.06

1.51 (0.67–3.40)

0.32

 <70 Gy

145

85

   

≧70 Gy

265

92

   

Hyperthermia

  

0.18

1.21 (0.65–2.26)

0.54

 Yes

141

86

   

 No

269

88

   

Prostate MRI study

  

0.33

1.57 (0.89–2.77)

0.12

 Yes

189

86

   

 No

221

90

   
  1. bRFS biochemical relapse-free survival, EBRT external beam radiation therapy, MRI magnetic resonance imaging, OR odds ratio, CI confidence interval.
  2. aT stage after prostate MRI.
  3. bExcluding 1 patient with unknown iPSA.
  4. cExcluding 10 patients with unknown Gleason scores.
  5. dExcluding 5 patients with an unknown risk group status.
  6. eExcluding 9 patients without ADT.
  7. fThe 388 evaluable patients with complete factors.
Back to article page